Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Vaccine. 2011 Dec 4;30(5):922–930. doi: 10.1016/j.vaccine.2011.11.089

Fig. 2.

Fig. 2

Mutant Q105N limits exposure of antibody epitopes overlapping the CD4bs. The antigenicity of hyperglycosylated mutant Q105N relative to gp120wt (JR-FL) was determined using mAbs F105, b6, VRC01, b13, B4e8, b12, 2G12, CD4-IgG2 and VRC0. CD4-IgG2 was used as a surrogate for CD4. Error bars denote the signal ranges from replicate wells.